Market Cap
$1.6B
IMCR
Immunocore Holdings plc
$29.71 ▼ -2.72%
Prev close $30.54Market cap$1.6B
ConsensusBuy
12-mo target$62.73 (+111.1%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)18 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on IMCR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (77%)
Inst. Holders
50 funds
Inst. Value
$1.0B
Inst. Activity
18 buys / 14 sells
SEC Reports
4
Press Releases
3
Price chart 30d -20.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 SEC
Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM registrational trial evalu
8-K — Impact 6/10
Sep 1, 2026 other
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences
Aug 20, 2026 Event
Aug 6, 2026 SEC KIMMTRAK
BOXED WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or li
Immunocore reported Q2 2026 KIMMTRAK revenue of $115.9M (+18% YoY), beating consensus of $110.4M, but posted a small net
8-K — Impact 5/10
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
1,597,037 shares ($50.7M)
Jun 30, 2026 Inst.
May 31, 2026 Press BlackRock, Inc. — ADD
1,004,598 shares ($31.9M)
Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing
Impact 6/10
May 27, 2026 Insider
Herbst Roy Steven was granted 27,492 shares
Director
Analyst ratings buy % -1.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
77% rate it Buy or better · 22 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 3, 2026 | Mizuho | MAINTAIN | Neutral | 52% |
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 5 | 0 | 0 | 77% | |
| Aug 1, 2026 | 6 | 10 | 5 | 0 | 0 | 76% | |
| Jul 1, 2026 | 7 | 10 | 5 | 0 | 0 | 77% | |
| Jun 1, 2026 | 7 | 11 | 5 | 0 | 0 | 78% | |
| May 1, 2026 | 7 | 11 | 5 | 0 | 0 | 78% | |
| Apr 1, 2026 | 7 | 11 | 5 | 0 | 0 | 78% | |
| Mar 1, 2026 | 8 | 11 | 4 | 0 | 0 | 83% | |
| Feb 1, 2026 | 8 | 11 | 4 | 0 | 0 | 83% |
Price targets
Where 11 covering analysts think IMCR trades over the next 12 months.
$62.73 +111.1% upside Strong Buy
Current$29.71 Low$34.00 Median$60.00 High$100.00 11 analysts
$34.00$100.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 2 bullish, 0 bearish, 1 mixed, 1 neutral · avg impact 5.3/10.Plus 3 press releases.
BULLISH8-K6/10
Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM regist
Sep 14, 2026
MIXED8-K5/10
Immunocore reported Q2 2026 KIMMTRAK revenue of $115.9M (+18% YoY), beating consensus of $110.4M, bu
Aug 6, 2026
NEUTRAL1443/10
David Berman, an affiliate of Immunocore Holdings plc, filed a Form 144 to notify intent to sell 25,
Apr 8, 2026
BULLISH8-K7/10
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $
Feb 25, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 1, 2026
other
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences
Aug 20, 2026
ftd
FTD: IMCR — 19,780 shares ($0.7M) failed to deliver
Settlement: 20260820, Price: $36.86, FTD Value: $729,090.8, IMMUNOCORE HLDGS PLC ADS
Aug 20, 2026
FDA
KIMMTRAK
BOXED WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIM
Aug 10, 2026
ftd
FTD: IMCR — 36,955 shares ($1.3M) failed to deliver
Settlement: 20260810, Price: $34.00, FTD Value: $1,256,470, IMMUNOCORE HLDGS PLC ADS
Aug 6, 2026
earnings_calendar
IMCR Q2 2026 Earnings Before Market Open — 2026-08-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.12 | $-0.26–$0.02 | 0.0% | -2.8% | 1↑ 9↓ | $0.1B | 12 |
| Next Q | $-0.18 | $-0.53–$0.09 | 70.2% | +4.9% | 3↑ 6↓ | $0.1B | 12 |
| Current FY | $-0.04 | $-0.46–$0.29 | 94.3% | +19.7% | 5↑ 6↓ | $0.5B | 11 |
| Next FY | $-0.75 | $-3.89–$1.30 | -970.1% | -0.5% | 2↑ 9↓ | $0.5B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.124 | — |
| 7d ago | $-0.120 | -0.003 |
| 30d ago | $-0.120 | -0.003 |
| 60d ago | $0.012 | -0.136 |
| 90d ago | $-0.014 | -0.110 |
Institutional ownership
Which big funds own IMCR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.0B total value (31,537,841 shares) as of 2026-Q2. Top holders: WELLINGTON, RTW, FMR. Net buying activity: 18 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 5,721,945 | $181.7M | 18.1% | — |
| RTW INVESTMENTS, LP | 4,869,798 | $154.6M | 15.4% | — |
| FMR LLC | 4,307,246 | $136.8M | 13.7% | — |
| PRIMECAP MANAGEMENT CO/CA/ | 3,638,241 | $115.5M | 11.5% | — |
| TWO SIGMA INVESTMENTS, LP | 1,648,983 | $52.4M | 5.2% | — |
| MILLENNIUM MANAGEMENT LLC | 1,597,037 | $50.7M | 5.1% | ADD +29.1% |
| BlackRock, Inc. | 1,004,598 | $31.9M | 3.2% | ADD +53.1% |
| Point72 Asset Management, L.P. | 990,280 | $31.4M | 3.1% | DOUBLED +118.6% |
| Jupiter Topco LLC | 709,022 | $22.5M | 2.2% | — |
| MARSHALL WACE, LLP | 590,941 | $18.8M | 1.9% | DOUBLED +227.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | ADD | 1,237,403 | 1,597,037 | +29.1% | $50.7M |
| BlackRock, Inc. | ADD | 656,309 | 1,004,598 | +53.1% | $31.9M |
| MARSHALL WACE, LLP | DOUBLED | 180,340 | 590,941 | +227.7% | $18.8M |
| CITADEL ADVISORS LLC | DOUBLED | 230,399 | 566,761 | +146.0% | $18.0M |
| Candriam S.C.A. | ADD | 269,729 | 373,046 | +38.3% | $11.8M |
| Legal & General Group Plc | ADD | 156,143 | 299,670 | +91.9% | $9.5M |
| MORGAN STANLEY | TRIM | 323,606 | 187,850 | -42.0% | $6.0M |
| Caption Management, LLC | TRIM | 661,786 | 172,503 | -73.9% | $5.5M |
| Jump Financial, LLC | DOUBLED | 38,498 | 131,949 | +242.7% | $4.2M |
| BANK OF AMERICA CORP /DE/ | TRIM | 206,866 | 116,144 | -43.9% | $3.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 6 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Herbst Roy Steven | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Bell John Irving | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Peterson Kristine | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Ratcliffe Peter John | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Pao William | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Kaul Siddharth | Director | AWARD | 27,492 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IMCR.
Shares short
7,770,242
Settlement Sep 15, 2026
Change vs prior
-0.3%
Semi-monthly cycle
Days to cover
20.6
At avg daily volume
Of shares outstanding
≈15.1%
Estimate — not % of float
All IMCR filing & press-release reports (7)
- 8-K reportSep 14, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportMay 31, 2026
- PRESS-RELEASE reportApr 19, 2026
- 144 reportApr 8, 2026
- PRESS-RELEASE reportMar 17, 2026
- 8-K reportFeb 25, 2026